Drug Profile
Research programme: rheumatoid arthritis therapy - GC Pharma
Latest Information Update: 07 Feb 2018
Price :
$50
*
At a glance
- Originator Green Cross
- Class
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 09 Mar 2006 Preclinical trials in Rheumatoid arthritis in South Korea (unspecified route)